mTOR at the crossroads of T cell proliferation and tolerance

Seminars in Immunology

Volumn 19, Issue 3, 2007, Pages 162-172

  Mondino, Anna ^a   Mueller, Daniel L ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anergy; CD4+ T cells; mTOR; Proliferation

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TOLL LIKE RECEPTOR;

CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MEMBRANE; CLONAL ANERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL PROLIFERATION; CLONAL ANERGY; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 34249284512     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2007.02.008     Document Type: Review

References (129)

1. Itano A.A., and Jenkins M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4 8 (2003) 733-739
2. Viola A., and Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273 (1996) 104-106
3. Monks C.R., Freiberg B.A., Kupfer H., Sciaky N., and Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395 6697 (1998) 82-86
4. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285 5425 (1999) 221-227
5. Mempel T.R., Henrickson S.E., and Von Andrian U.H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 6970 (2004) 154-159
6. Samelson L.E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 20 (2002) 371-394
7. Kaibuchi K., Takai Y., Sawamura M., Hoshijima M., Fujikura T., and Nishizuka Y. Synergistic functions of protein phosphorylation and calcium mobilization in platelet activation. J Biol Chem 258 11 (1983) 6701-6704
8. Berridge M.J. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 220 (1984) 345-360
9. Jenkins M.K., Pardoll D.M., Mizuguchi J., Chused T.M., and Schwartz R.H. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci USA 84 (1987) 5409-5413
10. Jain J., McCaffrey P.G., Miner Z., Kerppola T.K., Lambert J.N., Verdine G.L., et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365 (1993) 352-355
11. Ebinu J.O., Stang S.L., Teixeira C., Bottorff D.A., Hooton J., Blumberg P.M., et al. RasGRP links T-cell receptor signaling to Ras. Blood 95 10 (2000) 3199-3203
12. Owaki H., Varma R., Gillis B., Bruder J.T., Rapp U.R., Davis L.S.G., et al. Raf-1 is required for T cell IL2 production. EMBO J 12 (1993) 4367-4373
13. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 6490 (1994) 527-532
14. Parry R.V., Reif K., Smith G., Sansom D.M., Hemmings B.A., and Ward S.G. Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur J Immunol 27 10 (1997) 2495-2501
15. Ward S.G., Westwick J., Hall N.D., and Sansom D.M. Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur J Immunol 23 10 (1993) 2572-2577
16. Truitt K.E., Hicks C.M., and Imboden J.B. Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med 179 (1994) 1071-1076
17. Okkenhaug K., Wu L., Garza K.M., La Rose J., Khoo W., Odermatt B., et al. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol 2 4 (2001) 325-332
18. Wulfing C., and Davis M.M. A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science 282 (1998) 2266-2269
19. Viola A., Schroeder S., Sakakibara Y., and Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283 (1999) 680-682
20. Bromley S.K., Iaboni A., Davis S.J., Whitty A., Green J.M., Shaw A.S., et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol 2 12 (2001) 1159-1166
21. Lee K.H., Holdorf A.D., Dustin M.L., Chan A.C., Allen P.M., and Shaw A.S. T cell receptor signaling precedes immunological synapse formation. Science 295 5559 (2002) 1539-1542
22. Huppa J.B., Gleimer M., Sumen C., and Davis M.M. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 4 8 (2003) 749-755
23. Lee K.Y., D'Acquisto F., Hayden M.S., Shim J.H., and Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 308 5718 (2005) 114-118
24. Sanchez-Lockhart M., Marin E., Graf B., Abe R., Harada Y., Sedwick C.E., et al. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J Immunol 173 12 (2004) 7120-7124
25. Friend L.D., Shah D.D., Deppong C., Lin J., Bricker T.L., Juehne T.I., et al. A dose-dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted knockin mutant. J Exp Med 203 9 (2006) 2121-2133
26. Su B., Jacinto E., Hibi M., Kallunki T., Karin M., and Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77 (1994) 727-736
27. Salojin K.V., Zhang J., and Delovitch T.L. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. J Immunol 163 (1999) 844-853
28. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., and Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99 21 (2002) 13571-13576
29. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17 15 (2003) 1829-1834
30. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 9 (2002) 648-657
31. Plas D.R., and Thompson C.B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278 14 (2003) 12361-12366
32. Tee A.R., Anjum R., and Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase (PI3K)/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 278 39 (2003) 37288-37296
33. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 2 (2002) 177-189
34. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 2 (2002) 163-175
35. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 7092 (2006) 424-430
36. Edinger A.L., and Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13 7 (2002) 2276-2288
37. Edinger A.L., and Thompson C.B. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23 33 (2004) 5654-5663
38. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 178 4 (2007) 2163-2170
39. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 5712 (2005) 1098-1101
40. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11 6 (2006) 859-871
41. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 1 (2006) 125-137
42. Charvet C., Canonigo A.J., Becart S., Maurer U., Miletic A.V., Swat W., et al. Vav1 promotes T cell cycle progression by linking TCR/CD28 costimulation to FOXO1 and p27kip1 expression. J Immunol 177 8 (2006) 5024-5031
43. Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16 6 (2002) 769-777
44. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280 37 (2005) 32081-32089
45. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 5 (2003) 577-590
46. Li W., Whaley C.D., Bonnevier J.L., Mondino A., Martin M.E., Aagaard-Tillery K.M., et al. CD28 signaling augments Elk-1-dependent transcription at the c-fos gene during antigen stimulation. J Immunol 167 2 (2001) 827-835
47. Nandiwada S.L., Li W., Zhang R., and Mueller D.L. p300/Cyclic AMP-responsive element binding-binding protein mediates transcriptional coactivation by the CD28 T cell costimulatory receptor. J Immunol 177 1 (2006) 401-413
48. Yu C.T., Shih H.M., and Lai M.Z. Multiple signals required for cyclic AMP-responsive element binding protein (CREB) binding protein interaction induced by CD3/CD28 costimulation. J Immunol 166 1 (2001) 284-292
49. Shaulian E., and Karin M. AP-1 in cell proliferation and survival. Oncogene 20 19 (2001) 2390-2400
50. Colombetti S., Basso V., Mueller D.L., and Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 176 5 (2006) 2730-2738
51. Appleman L.J., van Puijenbroek A.A., Shu K.M., Nadler L.M., and Boussiotis V.A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 168 6 (2002) 2729-2736
52. Kane L.P., Andres P.G., Howland K.C., Abbas A.K., and Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2 1 (2001) 37-44
53. Sanchez-Lockhart M., and Miller J. Engagement of CD28 outside of the immunological synapse results in up-regulation of IL-2 mRNA stability but not IL-2 transcription. J Immunol 176 8 (2006) 4778-4784
54. Khoruts A., Mondino A., Pape K.A., Reiner S.L., and Jenkins M.K. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 187 (1998) 225-236
55. Bonnevier J.L., Yarke C.A., and Mueller D.L. Sustained B7/CD28 interactions and resultant phosphatidylinositol 3-kinase activity maintain G(1)→S phase transitions at an optimal rate. Eur J Immunol 36 6 (2006) 1583-1597
56. Appleman L.J., Berezovskaya A., Grass I., and Boussiotis V.A. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 164 1 (2000) 144-151
57. Humbert P.O., Brumby A.M., Quinn L.M., and Richardson H.E. New tricks for old dogs: unexpected roles for cell cycle regulators revealed using animal models. Curr Opin Cell Biol 16 6 (2004) 614-622
58. Sherr C.J., and Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18 22 (2004) 2699-2711
59. Morice W.G., Brunn G.J., Wiederrecht G., Siekierka J.J., and Abraham R.T. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268 5 (1993) 3734-3738
60. Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H., et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372 6506 (1994) 570-573
61. Song J., Salek-Ardakani S., So T., and Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol (2006)
62. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 171 (1994) 131-137
63. Gett A.V., and Hodgkin P.D. A cellular calculus for signal integration by T cells. Nat Immunol 1 3 (2000) 239-244
64. Bonnevier J.L., and Mueller D.L. Cutting edge: B7/CD28 interactions regulate cell cycle progression independent of the strength of TCR signaling. J Immunol 169 12 (2002) 6659-6663
65. Wong P., and Pamer E.G. Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol 166 10 (2001) 5864-5868
66. van Stipdonk M.J., Lemmens E.E., and Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2 5 (2001) 423-429
67. Lee W.T., Pasos G., Cecchini L., and Mittler J.N. Continued antigen stimulation is not required during CD4(+) T cell clonal expansion. J Immunol 168 4 (2002) 1682-1689
68. Obst R., van Santen H.M., Mathis D., and Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J Exp Med 201 10 (2005) 1555-1565
69. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24 13 (2004) 6104-6115
70. Hammerman P.S., Fox C.J., Birnbaum M.J., and Thompson C.B. The Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood (2005)
71. Fox C.J., Hammerman P.S., and Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 201 2 (2005) 259-266
72. Nossal G.J., and Pike B.L. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA 77 3 (1980) 1602-1606
73. Jenkins M.K., and Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165 (1987) 302-319
74. Mueller D.L., Jenkins M.K., and Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7 (1989) 445-480
75. Jenkins M.K., Chen C.A., Jung G., Mueller D.L., and Schwartz R.H. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 144 (1990) 16-22
76. Sloan-Lancaster J., Evavold B.D., and Allen P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363 (1993) 156-159
77. Mirshahidi S., Huang C.T., and Sadegh-Nasseri S. Anergy in peripheral memory CD4(+) T cells induced by low avidity engagement of T cell receptor. J Exp Med 194 6 (2001) 719-731
78. DeSilva D.R., Urdahl K.B., and Jenkins M.K. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 147 (1991) 3261-3267
79. Gilbert K.M., and Weigle W.O. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 151 (1993) 1245-1254
80. Powell J.D., Lerner C.G., and Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 162 (1999) 2775-2784
81. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305-334
82. Rammensee H.G., Kroschewski R., and Frangoulis B. Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. Nature 339 (1989) 541-544
83. Rocha B., Tanchot C., and von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 177 (1993) 1517-1521
84. Perez V.L., Van Parijs L., Biuckians A., Zheng X.X., Strom T.B., and Abbas A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6 4 (1997) 411-417
85. Pape K.A., Merica R., Mondino A., Khoruts A., and Jenkins M.K. Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J Immunol 160 (1998) 4719-4729
86. Chiodetti L., Choi S., Barber D.L., and Schwartz R.H. Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol 176 4 (2006) 2279-2291
87. Tanchot C., Barber D.L., Chiodetti L., and Schwartz R.H. Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation. J Immunol 167 (2001) 2030-2039
88. Quill H., and Schwartz R.H. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 138 (1987) 3704-3712
89. Gajewski T.F., Fields P., and Fitch F.W. Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol 25 7 (1995) 1836-1842
90. Telander D.G., Malvey E.N., and Mueller D.L. Evidence for repression of IL-2 gene activation in anergic T cells. J Immunol 162 3 (1999) 1460-1465
91. Macian F., Garcia-Cozar F., Im S.H., Horton H.F., Byrne M.C., and Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109 6 (2002) 719-731
92. Kowalski J., Drake C., Schwartz R.H., and Powell J. Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes. Bioinformatics 20 3 (2004) 364-373
93. Safford M., Collins S., Lutz M.A., Allen A., Huang C.T., Kowalski J., et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6 5 (2005) 472-480
94. Harris J.E., Bishop K.D., Phillips N.E., Mordes J.P., Greiner D.L., Rossini A.A., et al. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol 173 12 (2004) 7331-7338
95. Bhandoola A., Cho E.A., Yui K., Saragovi H.U., Greene M.I., and Quill H. Reduced CD3-mediated protein tyrosine phosphorylation in anergic CD4+ and CD8+ T cells. J Immunol 151 (1993) 2355-2367
96. Migita K., Eguchi K., Kawabe Y., Tsukada T., Ichinose Y., Nagataki S., et al. Defective TCR-mediated signaling in anergic T cells. J Immunol 155 11 (1995) 5083-5087
97. Asai K., Hachimura S., Kimura M., Toraya T., Yamashita M., Nakayama T., et al. T cell hyporesponsiveness induced by oral administration of ovalbumin is associated with impaired NFAT nuclear translocation and p27kip1 degradation. J Immunol 169 9 (2002) 4723-4731
98. Fields P.E., Gajewski T.F., and Fitch F.W. Blocked Ras activation in anergic CD4+ T cells. Science 271 (1996) 1276-1278
99. Li W., Whaley C.D., Mondino A., and Mueller D.L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271 (1996) 1272-1276
100. DeSilva D.R., Feeser W.S., Tancula E.J., and Scherle P.A. Anergic T cells are defective in both Jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways. J Exp Med 183 (1996) 2017-2023
101. Mondino A., Whaley C.D., DeSilva D.R., Li W., Jenkins M.K., and Mueller D.L. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J Immunol 157 (1996) 2048-2057
102. Stefanova I., Hemmer B., Vergelli M., Martin R., Biddison W.E., and Germain R.N. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 4 3 (2003) 248-254
103. Mueller D.L. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5 9 (2004) 883-890
104. Heissmeyer V., Macian F., Im S.H., Varma R., Feske S., Venuprasad K., et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5 3 (2004) 255-265
105. Boussiotis V.A., Freeman G.J., Berezovskaya A., Barber D.L., and Nadler L.M. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 278 (1997) 124-128
106. Zha Y., Marks R., Ho A.W., Peterson A.C., Janardhan S., Brown I., et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 7 11 (2006) 1166-1173
107. Kang S.M., Beverly B., Tran A.C., Brorson K., Schwartz R.H., and Lenardo M.J. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257 5073 (1992) 1134-1138
108. Powell J.D., Lerner C.G., Ewoldt G.R., and Schwartz R.H. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 163 12 (1999) 6631-6639
109. Tzachanis D., Freeman G.J., Hirano N., van Puijenbroek A.A., Delfs M.W., Berezovskaya A., et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2 12 (2001) 1174-1182
110. Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6 (2000) 290-297
111. Li L., Iwamoto Y., Berezovskaya A., and Boussiotis V.A. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 7 11 (2006) 1157-1165
112. Jackson S.K., DeLoose A., and Gilbert K.M. Induction of anergy in Th1 cells associated with increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J Immunol 166 2 (2001) 952-958
113. Powell J.D., Bruniquel D., and Schwartz R.H. TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol 31 12 (2001) 3737-3746
114. Colombetti S., Benigni F., Basso V., and Mondino A. Clonal anergy is maintained independently of T cell proliferation. J Immunol 169 11 (2002) 6178-6186
115. Crespi D., Massa S., Basso V., Colombetti S., Mueller D.L., and Mondino A. Constitutive active p21ras enhances primary T cell responsiveness to Ca2+ signals without interfering with the induction of clonal anergy. Eur J Immunol 32 9 (2002) 2500-2509
116. Beverly B., Kang S.M., Lenardo M.J., and Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4 (1992) 661-671
117. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266 5187 (1994) 1039-1042
118. Allen A., Zheng Y., Gardner L., Safford M., Horton M.R., and Powell J.D. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 172 8 (2004) 4797-4803
119. Song K., Wang H., Krebs T.L., and Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J 25 1 (2006) 58-69
120. Vanasek T.L., Khoruts A., Zell T., and Mueller D.L. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol 167 10 (2001) 5636-5644
121. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 12 (2005) 4743-4748
122. Valmori D., Tosello V., Souleimanian N.E., Godefroy E., Scotto L., Wang Y., et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 177 2 (2006) 944-949
123. Rohde J.R., and Cardenas M.E. The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. Mol Cell Biol 23 2 (2003) 629-635
124. Tsang C.K., Bertram P.G., Ai W., Drenan R., and Zheng X.F. Chromatin-mediated regulation of nucleolar structure and RNA Pol I localization by TOR. EMBO J 22 22 (2003) 6045-6056
125. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 12 (2003) 1206-1212
126. Cherkasova V.A., and Hinnebusch A.G. Translational control by TOR and TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev 17 7 (2003) 859-872
127. Kubota H., Obata T., Ota K., Sasaki T., and Ito T. Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2. J Biol Chem 278 23 (2003) 20457-20460
128. Munn D.H., Sharma M.D., Baban B., Harding H.P., Zhang Y., Ron D., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22 5 (2005) 633-642
129. Vanasek T.L., Nandiwada S.L., Jenkins M.K., and Mueller D.L. CD25+Foxp3+ regulatory T cells facilitate CD4+ T cell clonal anergy induction during the recovery from lymphopenia. J Immunol 176 10 (2006) 5880-5889